By Kaplan-Meier analysis, tumor size was a significant predictor of both overall (p = 0.03) and disease-specific (p = 0.02) mortality. However, tumor size approached but did not attain statistical ...

– Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All participants with disease control experienced a ...

Glioblastoma, one of the most aggressive and lethal brain cancers, has a five-year survival rate of only 6.9%, according to the National Brain Tumor Society. While the relationship between ...

Positive preliminary data from the phase 1b/2 trial evaluating Olvi-Vec in small cell lung cancer have been announced.

The Food and Drug Administration (FDA) has approved Romvimza ™ (vimseltinib) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will ...

Hoth Therapeutics (HOTH) announced breakthrough preclinical findings demonstrating the efficacy of HT-KIT, a novel targeted therapy for ...

Doctors stage non-small cell lung cancer (NSCLC ... The cancer hasn’t reached distant body parts (MO). At stage 4, the tumor may be any size, and the cancer may have extended into nearby ...